AAAAAA

   
Results: 1-8 |
Results: 8
COMPARISON OF 5-FLUOROURACIL PHARMACOKINETICS IN PATIENTS RECEIVING CONTINUOUS 5-FLUOROURACIL INFUSION AND ORAL URACIL PLUS N-1-(2'-TETRAHYDROFURYL)-5-FLUOROURACIL
Authors: HO DH PAZDUR R COVINGTON W BROWN N HUO YY LASSERE Y KURITANI J
Citation: Dh. Ho et al., COMPARISON OF 5-FLUOROURACIL PHARMACOKINETICS IN PATIENTS RECEIVING CONTINUOUS 5-FLUOROURACIL INFUSION AND ORAL URACIL PLUS N-1-(2'-TETRAHYDROFURYL)-5-FLUOROURACIL, Clinical cancer research, 4(9), 1998, pp. 2085-2088
PHASE-I STUDY OF THE NEW CAMPTOTHECIN ANALOG DX-8951F ADMINISTERED BY24-HOUR CONTINUOUS-INFUSION
Authors: HOFF PM LASSERE Y ROYCE M MATEI C SLAUGHTER M MEDGYESY D LEE J COYLE J DEJAGER RL PAZDUR R
Citation: Pm. Hoff et al., PHASE-I STUDY OF THE NEW CAMPTOTHECIN ANALOG DX-8951F ADMINISTERED BY24-HOUR CONTINUOUS-INFUSION, Annals of oncology, 9, 1998, pp. 246-246
UFT, ORAL LEUCOVORIN (LV) AND RADIOTHERAPY (RT) FOR PATIENTS WITH RESECTABLE RECTAL-CARCINOMA - AN EFFECTIVE ORAL PREOPERATIVE REGIMEN
Authors: HOFF PM BRITO R SLAUGHTER M MATEI C LASSERE Y JANJAN N SKIBBER J RANDOLPH J BENNER S PAZDUR R ANDERSON MD
Citation: Pm. Hoff et al., UFT, ORAL LEUCOVORIN (LV) AND RADIOTHERAPY (RT) FOR PATIENTS WITH RESECTABLE RECTAL-CARCINOMA - AN EFFECTIVE ORAL PREOPERATIVE REGIMEN, Annals of oncology, 9, 1998, pp. 595-595
PHASE-I TRIAL OF URACIL-TEGAFUR (UFT) PLUS ORAL LEUCOVORIN - 28-DAY SCHEDULE
Authors: PAZDUR R LASSERE Y DIAZCANTON E HO DH
Citation: R. Pazdur et al., PHASE-I TRIAL OF URACIL-TEGAFUR (UFT) PLUS ORAL LEUCOVORIN - 28-DAY SCHEDULE, Cancer investigation, 16(3), 1998, pp. 145-151
PHASE-I TRIAL OF URACIL-TEGAFUR (UFT) PLUS ORAL LEUCOVORIN - 14-DAY SCHEDULE
Authors: PAZDUR R LASSERE Y DIAZCANTON E BREADY B HO DH
Citation: R. Pazdur et al., PHASE-I TRIAL OF URACIL-TEGAFUR (UFT) PLUS ORAL LEUCOVORIN - 14-DAY SCHEDULE, Investigational new drugs, 15(2), 1997, pp. 123-128
PHASE-I TRIALS OF URACIL-TEGAFUR (UFT) USING 5 AND 28 DAY ADMINISTRATION SCHEDULES - DEMONSTRATION OF SCHEDULE-DEPENDENT TOXICITIES
Authors: PAZDUR R LASSERE Y DIAZCANTON E BREADY B HO DH
Citation: R. Pazdur et al., PHASE-I TRIALS OF URACIL-TEGAFUR (UFT) USING 5 AND 28 DAY ADMINISTRATION SCHEDULES - DEMONSTRATION OF SCHEDULE-DEPENDENT TOXICITIES, Anti-cancer drugs, 7(7), 1996, pp. 728-733
PHASE-II TRIAL OF DOCETAXEL (TAXOTERE(R)) IN METASTATIC COLORECTAL-CARCINOMA
Authors: PAZDUR R LASSERE Y SOH LT AJANI JA BREADY B SOO E SUGARMAN S PATT Y ABBRUZZESE JL LEVIN B
Citation: R. Pazdur et al., PHASE-II TRIAL OF DOCETAXEL (TAXOTERE(R)) IN METASTATIC COLORECTAL-CARCINOMA, Annals of oncology, 5(5), 1994, pp. 468-470
PHASE-II TRIAL OF URACIL AND TEGAFUR PLUS ORAL LEUCOVORIN - AN EFFECTIVE ORAL REGIMEN IN THE TREATMENT OF METASTATIC COLORECTAL-CARCINOMA
Authors: PAZDUR R LASSERE Y RHODES V AJANI JA SUGARMAN SM PATT YZ JONES DV MARKOWITZ AB ABBRUZZESE JL BREADY B LEVIN B
Citation: R. Pazdur et al., PHASE-II TRIAL OF URACIL AND TEGAFUR PLUS ORAL LEUCOVORIN - AN EFFECTIVE ORAL REGIMEN IN THE TREATMENT OF METASTATIC COLORECTAL-CARCINOMA, Journal of clinical oncology, 12(11), 1994, pp. 2296-2300
Risultati: 1-8 |